Advaxis Inc. (NASDAQ:ADXS)’s share price fell 4.3% during trading on Tuesday . The stock traded as low as $14.12 and last traded at $14.18, with a volume of 1,184,992 shares changing hands. The stock had previously closed at $14.81.

Several brokerages have recently commented on ADXS. Jefferies Group reiterated a “buy” rating on shares of Advaxis in a research report on Thursday, August 4th. HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research report on Friday, August 5th. Barclays PLC increased their price objective on Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, August 3rd. Finally, FBR & Co reiterated an “outperform” rating and set a $34.00 price objective on shares of Advaxis in a research report on Thursday, July 7th. Six analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $25.80.

The company’s market cap is $482.90 million. The stock has a 50-day moving average of $9.86 and a 200-day moving average of $8.49.

In other news, Director Richard J. Berman sold 18,000 shares of the business’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $15.21, for a total value of $273,780.00. Following the transaction, the director now directly owns 66,430 shares in the company, valued at $1,010,400.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Sidransky sold 22,808 shares of the business’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total value of $342,348.08. Following the completion of the transaction, the director now owns 91,759 shares in the company, valued at $1,377,302.59. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.